India markets closed
  • BSE SENSEX

    52,588.71
    +14.25 (+0.03%)
     
  • Nifty 50

    15,772.75
    +26.25 (+0.17%)
     
  • Dow

    33,890.21
    +13.24 (+0.04%)
     
  • Nasdaq

    14,207.68
    +66.20 (+0.47%)
     
  • BTC-INR

    2,410,744.00
    +8,722.25 (+0.36%)
     
  • CMC Crypto 200

    773.72
    -20.61 (-2.59%)
     
  • Hang Seng

    28,309.76
    -179.24 (-0.63%)
     
  • Nikkei

    28,884.13
    +873.20 (+3.12%)
     
  • EUR/INR

    88.8011
    +0.4218 (+0.48%)
     
  • GBP/INR

    103.6756
    +0.3821 (+0.37%)
     
  • AED/INR

    20.2030
    +0.0650 (+0.32%)
     
  • INR/JPY

    1.4858
    +0.0008 (+0.05%)
     
  • SGD/INR

    55.3250
    +0.1130 (+0.20%)
     

Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

Seres Therapeutics, Inc., (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.

A live audio webcast of the panel will be available under the "Investors and News" section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and plans to initiate a clinical program with SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005069/en/

Contacts

PR Contact
Kristin Ainsworth
kainsworth@serestherapeutics.com

IR Contact
Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting